@article{5fe23e58aae04aa4890dda6b6c2963e9,
title = "A defect in COPI-mediated transport of STING causes immune dysregulation in COPA syndrome",
abstract = "Pathogenic COPA variants cause a Mendelian syndrome of immune dysregulation with elevated type I interferon signaling. COPA is a subunit of coat protein complex I (COPI) that mediates Golgi to ER transport. Missense mutations of the COPAWD40 domain impair binding and sorting of proteins targeted for ER retrieval, but how this causes disease remains unknown. Given the importance of COPA in Golgi-ER transport, we speculated that type I interferon signaling in COPA syndrome involves missorting of STING. We show that a defect in COPI transport causes ligand-independent activation of STING. Furthermore, SURF4 is an adapter molecule that facilitates COPA-mediated retrieval of STING at the Golgi. Activated STING stimulates type I interferon-driven inflammation in CopaE241K/+ mice that is rescued in STING-deficient animals. Our results demonstrate that COPA maintains immune homeostasis by regulating STING transport at the Golgi. In addition, activated STING contributes to immune dysregulation in COPA syndrome and may be a new molecular target in treating the disease.",
author = "Zimu Deng and Zhenlu Chong and Law, {Christopher S.} and Kojiro Mukai and Ho, {Frances O.} and Tereza Martinu and Backes, {Bradley J.} and Eckalbar, {Walter L.} and Tomohiko Taguchi and Shum, {Anthony K.}",
note = "Funding Information: This work was supported by the UCSF Program for Break-through Biomedical Research, funded in part by the Sandler Foundation (to A.K. Shum); National Institutes of Health (NIH)/ National Institute of Allergy and Infectious Diseases (NIAID) R01AI137249 (to A.K. Shum), NIH/National Heart, Lung, and Blood Institute (NHLBI) R01HL122533 (to A.K. Shum), NIH/ NHLBI R00HL135403 (to W.L. Eckalbar), and NIH/NHLBI PO1HL103453 (Suzy A.A. Comhair and Serpil C. Erzurum); Japan Society for the Promotion of Science KAKENHI grants JP19H00974 (to T. Taguchi), JP15H05903 (to T. Taguchi), JP17K15445 (to K. Mukai), and JP20H03202 (to K. Mukai); and AMED-PRIME (17939604 to T. Taguchi). Funding Information: Disclosures: T. Martinu reported grants from Sanofi and nonfinancial support from APCBio outside the submitted work. No other disclosures were reported. Publisher Copyright: {\textcopyright} 2020 Rockefeller University Press. All rights reserved.",
year = "2020",
month = jul,
doi = "10.1084/JEM.20201045",
language = "English",
volume = "217",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "11",
}